

# Pagelopolus Endocrinology

## Estradiol Pellet Implantation Bill of Materials (BOM)

Document type: Procedure support document Version date: 2026-02-26 Intended users: Licensed clinicians and trained clinical staff only

### 1. Purpose

This BOM separates disposable kit components from clinic-stock medications and safety items for subcutaneous estradiol pellet insertion. Material selection is based on the source insertion workflow and infection-control standards. [R1][R2][R3][R4]

### 2. Per-Procedure Core Kit (Sterile Field)

Item	Minimum specification	Typical quantity per case	Source basis
Disposable trocar kit	3-piece sterile trocar set; size selected per pellet count (commonly 3.2-4.5 mm)	1	[R1]
Fenestrated sterile drape	Single-use, sterile	1	[R1]
Sterile gloves	Correct size for operator (and assistant if needed)	1-2 pairs	[R1][R2]
Skin prep swabs	Povidone-iodine or alcohol-based chlorhexidine per clinic protocol	1 set	[R1][R4]
Alcohol wipes	For vial tops and local cleanup	2-4	[R1][R3]
10 mL sterile syringe	Luer lock preferred	1	[R1]
18-25G draw/infiltration needles	Per medication prep protocol	1-2	[R1][R3]
#11 sterile blade	For small transverse incision	1	[R1]
Sterile forceps	For pellet loading	1	[R1]
Sterile gauze pads	Hemostasis and dressing support	2-6	[R1]
Skin closure strips	Steri-Strips or paper skin tape	2-4 strips	[R1]
Outer dressing	Sterile adhesive gauze or equivalent	1	[R1]

### 3. Clinic-Stock Medications and Procedure Consumables

Item	Minimum specification	Typical quantity per case	Source basis
Estradiol pellets	Prescribed strength, lot-tracked	Per order	[R1][R6][R7]

Item	Minimum specification	Typical quantity per case	Source basis
Lidocaine 1%	With or without epinephrine per patient risk/allergy profile	3-6 mL typical local use	[R1]
Sodium bicarbonate	For buffering local anesthetic if used by protocol	2-3 mL typical	[R1][R8][R9]
Sterile saline (optional)	For protocol-specific flush/prep needs	PRN	[R2][R3]
Sharps container	At point of use	1 available	[R3]
Biohazard waste supplies	Red bag and disposal pathway	1 set available	[R2][R3]

#### 4. Safety and Readiness Items

Item	Why it is required	Source basis
Time-out checklist	Verifies identity, site, laterality, implants, consent, allergies	[R10]
Emergency response kit	Required for rare acute medication or vasovagal events	[R2]
Blood pressure and pulse monitoring capability	Immediate post-procedure safety check	[R2]
Adverse-event reporting workflow	Needed for post-market safety reporting, including compounded products	[R7]

#### 5. Documentation Supplies

Item	Required fields	Source basis
Procedure note template	Site, anesthesia used, incision method, pellet count, tolerance, complications	[R1][R2]
Implant log	Product name, concentration, lot number, expiration, quantity, insertion site	[R1][R2]
Discharge instruction form	Activity limits, wound care, warning signs, contact route	[R1][R2][R11]
Consent packet set	Therapy consent, procedure consent, anesthesia consent, compounded-medication acknowledgment	[R5][R6][R7]

#### 6. Recommended Par-Level Baseline (Starter)

For every 25 planned procedures/month:

- Trocar kits: 30

- Fenestrated drapes: 35
- Sterile gloves: 75 pairs (mixed sizes)
- #11 blades: 40
- Sterile forceps (single-use): 35
- Steri-Strips and dressings: 60 each
- Syringes and needles: 75 each
- Alcohol wipes: 300
- Skin prep swabs: 100 sets

This is an operational estimate and should be adjusted using your actual monthly utilization and waste rate.

## References

- [R1] Trocar Supplies. Hormone Pellet Therapy and Insertion Procedure. <https://trocarsupplies.com/pages/insertion-procedure>
- [R2] CDC. Core Infection Prevention and Control Practices for Safe Healthcare Delivery in All Settings. <https://www.cdc.gov/infection-control/hcp/core-practices/index.html>
- [R3] CDC. Injection Safety. <https://www.cdc.gov/injection-safety/about/index.html>
- [R4] WHO. Global Guidelines for the Prevention of Surgical Site Infection (alcohol-based antiseptic skin prep recommendations). <https://www.ncbi.nlm.nih.gov/books/NBK401132/>
- [R5] Coleman E, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553112/>
- [R6] Endocrine Society Position Statement. Compounded Bioidentical Hormone Therapy. <https://www.endocrine.org/advocacy/position-statements/compounded-bioidentical-hormone-therapy>
- [R7] FDA. Menopause and Hormones: Common Questions (compounded hormones are not FDA approved). <https://www.fda.gov/consumers/womens-health-topics/menopause>
- [R8] Cepeda MS, et al. Adjusting the pH of lidocaine for reducing pain on injection. Cochrane Review. <https://pubmed.ncbi.nlm.nih.gov/12917913/>
- [R9] Bartfield JM, et al. Buffered versus plain lidocaine for local anesthesia in wound management. Ann Emerg Med. <https://pubmed.ncbi.nlm.nih.gov/8381259/>
- [R10] WHO. WHO Surgical Safety Checklist. <https://www.ncbi.nlm.nih.gov/books/NBK44249/>
- [R11] DailyMed. TESTOPEL (testosterone pellets) label (implant site adverse events). <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81310d87-0fd2-43d2-b493-629694e5e594>